Pfizer ROE 2010-2022 | PFE

Current and historical return on equity (ROE) values for Pfizer (PFE) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Pfizer ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2022-06-30 $29.31B $87.47B 36.23%
2022-03-31 $24.97B $82.69B 32.59%
2021-12-31 $21.98B $77.46B 30.05%
2021-09-30 $19.43B $75.97B 27.90%
2021-06-30 $12.76B $70.32B 19.03%
2021-03-31 $10.68B $68.87B 16.28%
2020-12-31 $9.16B $63.47B 14.15%
2020-09-30 $7.73B $65.50B 11.94%
2020-06-30 $13.94B $64.56B 21.55%
2020-03-31 $15.50B $65.34B 24.39%
2019-12-31 $16.03B $63.45B 25.86%
2019-09-30 $16.22B $65.40B 26.13%
2019-06-30 $12.65B $59.92B 19.88%
2019-03-31 $11.48B $59.16B 17.34%
2018-12-31 $11.15B $63.76B 16.16%
2018-09-30 $23.82B $71.66B 33.55%
2018-06-30 $22.55B $70.12B 32.98%
2018-03-31 $21.75B $70.54B 33.20%
2017-12-31 $21.31B $71.66B 34.06%
2017-09-30 $9.81B $61.11B 16.46%
2017-06-30 $8.32B $58.69B 13.82%
2017-03-31 $7.30B $58.75B 11.90%
2016-12-31 $7.22B $59.84B 11.55%
2016-09-30 $6.27B $63.60B 9.83%
2016-06-30 $7.04B $63.07B 10.90%
2016-03-31 $7.62B $63.35B 11.61%
2015-12-31 $6.96B $65.00B 10.43%
2015-09-30 $8.36B $67.12B 12.23%
2015-06-30 $8.90B $67.18B 12.50%
2015-03-31 $9.18B $67.59B 12.47%
2014-12-31 $9.14B $71.62B 11.98%
2014-09-30 $10.48B $78.31B 13.52%
2014-06-30 $10.40B $76.96B 13.42%
2014-03-31 $21.58B $78.07B 27.67%
2013-12-31 $22.00B $76.62B 27.78%
2013-09-30 $25.75B $78.35B 32.00%
2013-06-30 $26.37B $78.98B 32.39%
2013-03-31 $15.53B $82.83B 19.02%
2012-12-31 $14.57B $81.68B 17.80%
2012-09-30 $9.69B $82.12B 11.81%
2012-06-30 $10.22B $79.96B 12.14%
2012-03-31 $9.58B $83.68B 11.08%
2011-12-31 $10.01B $82.62B 11.35%
2011-09-30 $11.46B $90.53B 12.79%
2011-06-30 $8.59B $88.96B 9.65%
2011-03-31 $8.45B $90.53B 9.56%
2010-12-31 $8.26B $88.27B 9.35%
2010-09-30 $6.13B $88.07B 6.90%
2010-06-30 $8.15B $86.88B 9.77%
2010-03-31 $7.93B $90.08B 10.23%
2009-12-31 $8.64B $90.45B 12.32%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $245.597B $81.288B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $429.503B 16.35
Eli Lilly (LLY) United States $307.239B 38.96
AbbVie (ABBV) United States $237.296B 10.08
Novo Nordisk (NVO) Denmark $225.460B 29.74
Merck (MRK) United States $218.166B 11.39
Novartis AG (NVS) Switzerland $168.180B 12.40